ImmunityBio, Inc. (IBRX)
- Previous Close
4.2500 - Open
4.2700 - Bid 4.1700 x 300
- Ask 4.2600 x 300
- Day's Range
4.1800 - 4.4300 - 52 Week Range
1.2500 - 10.5300 - Volume
2,198,533 - Avg. Volume
3,228,230 - Market Cap (intraday)
2.932B - Beta (5Y Monthly) -0.31
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9600 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.38
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
immunitybio.comRecent News: IBRX
View MorePerformance Overview: IBRX
Trailing total returns as of 8/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IBRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IBRX
View MoreValuation Measures
Market Cap
2.93B
Enterprise Value
3.45B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.03k
Price/Book (mrq)
--
Enterprise Value/Revenue
2.64k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.04%
Return on Equity (ttm)
--
Revenue (ttm)
1.31M
Net Income Avi to Common (ttm)
-597.65M
Diluted EPS (ttm)
-0.9600
Balance Sheet and Cash Flow
Total Cash (mrq)
217.98M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-273.73M